Acute Kidney Injury, COVID-19, Renal Replacement Therapy
Conditions
Keywords
Acute Kidney Injury, SARS-CoV-2, Renal Replacement Therapy
Brief summary
Among patients with SARS-CoV-2 pneumonia, approximately 20% have an acute kidney injury (AKI) and 5% require renal replacement therapy. Occurrence of AKI in patients with COVID-19 is associated with increased morbidity and mortality. Early detection of patients at risk of AKI would allow to prevent onset or worsening of AKI. The aim of this study is to determine if urine biomarkers of renal tubular damage such as TIMP-2 and IGFBP7 could early identify patients with SARS-CoV-2 pneumonia at risk of developing AKI.
Interventions
OTHER[TIMP-2]*[IGFBP-7]
\[TIMP-2\]\*\[IGFBP-7\] mesurement in urine sample relicates of COVID-19 patients admitted to the Montpellier University Hospital
Sponsors
University Hospital, Montpellier
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years * COVID-19 confirmed by positive SARS-CoV-2 PCR * at least one urine sample
Exclusion criteria
* Persons under protection * Paritcipation rejections
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sensibility and specificity of urinary | Occurence of AKI 7 days after urinary biomarkers measurement | Sensibility and specificity of urinary \[TIMP-2\]\*\[IGFBP-7\] \> 0,3 to predict AKI (KDIGO stage ≥ 1) in SARS-CoV-2 patients at day-7 after measurement |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Sensibility and specificity of urinary | Occurnce of AKI worsening, renal replacement therapy requirement or persistant AKI, 7 days after urinary biomarkers mesurement | Sensibility and specificity of urinary \[TIMP-2\]\*\[IGFBP-7\] \> 0,3 to predict AKI worsening, renal replacement therapy requirement or persistant AKI |
Countries
France
Outcome results
None listed